Tysabri Touch Form Pdf. Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Verify that the patient is currently authorized to receive tysabri prior to each infusion provide the patient with a copy of the patient medication guide prior to each infusion
Tysabri Treatment Profile
Tysabri is a prescription medicine used to treat adults with: Information prescribers, infusion center healthcare providers, and patients with the risk of progressive multifocal leukoencephalopathy (pml) associated with tysabri including the increased risk of pml with treatment duration and prior immunosuppressant use. Maintain compliance with the touch prescribing program. Reduce administrative burden/paperwork for prescribers and infusion sites. Web the touch prescribing program has designed to: This document may not be part of the latest approved prescribing program tysabri outreach: Web our records indicate that ’s authorization to receive tysabri will expire on and he/she will no longer be able to receive tysabri. Tysabri increases the risk of pml. Unified commitment to health phone: Web tysabri increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (pml)—that most leads to death instead severe disability.
This is to make sure that you are informed about the risks of treatment with tysabri, including the risk of progressive multifocal leukoencephalopathy (pml). Web tysabri treatment continuation form tysabri (natalizumab) 300 mg concentrate solution for infusion this form should be read carefully before continuing tysabri treatment for more than 2 years. Web tysabri is an integrin receptor antagonist indicated for treatment of: Web tysabri increases your risk of getting a rare brain infection—called progressive multifocal leukoencephalopathy (pml)—that most leads to death instead severe disability. Verify that the patient is currently authorized to receive tysabri prior to each infusion provide the patient with a copy of the patient medication guide prior to each infusion Web the touch prescribing program has designed to: Web current as of 6/1/2013. Web per the requirements of the touch prescribing program, authorized infusion sites must: If diagnosis of relapsing forms of multiple sclerosis (ms). Although you have been receiving tysabri for 2 years, it is important that you are reminded that the risk of pml increases beyond this time. Unified commitment to health phone:
